List view / Grid view



Rigontec GmbH Appoints Dr. Christian Schetter as CEO

5 February 2015 | By Rigontec GmbH

Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the appointment of Dr. Christian Schetter as CEO...

First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme

3 February 2015 | By Innovative Medicines Initiative (IMI)

Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…

New targeted drugs could treat drug-resistant skin cancer

15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute

A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...

Send this to a friend